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Introduction
DNA and RNA are the most vital molecules that serve as the equivalent of an
enormous hard disk to store information. They also can be used as a diagnostic
gadget and therapeutic “doer”.1–4 The results from many types of research showed
that the speciﬁc structural characteristics of these molecules have opened new
research ﬁelds leading to the design of aptamers. Aptamers are oligonucleotides
including ssRNA, ssDNA (single-stranded RNA, DNA) or peptides that bind to
select targets with signiﬁcant dependency and exclusivity due to their speciﬁc
structural characteristics.5,6 Aptamers are known as an adequate alternative for
antibodies due to their ability to overcome the many disadvantages of using
antibodies.7–9 For example, it is well known that oligonucleotides are sturdier at
higher temperatures than proteins, so that they can sustain their structures over
frequent cycles of denaturation and renaturation. Therefore, the greatest beneﬁt of
aptamers based on oligonucleotides over antibodies based on proteins is their
constant properties at high temperatures, even after a 95 °C denaturation.10–13
Aptamers are minimally toxic molecules with low immunogenicity because nucleic
acids usually are not recognized as an external, foreign agent by the human immune
system.14,15 Aptamers are derived from SELEX (Systematic Evolution of Ligands by
Exponential Enrichment) or in vitro evolutionary processes, so toxins and other molecules that do not induce a strong immune response can be used as the object to develop
aptamers. Therefore, based on the advantages described above, aptamers are more
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Abstract: With the passage of time and more advanced societies, there is a greater emergence and incidence of disease and necessity for improved treatments. In this respect,
nowadays, aptamers, with their better efﬁciency at diagnosing and treating diseases than
antibodies, are at the center of attention. Here, in this review, we ﬁrst investigate aptamer
function in various ﬁelds (such as the detection and remedy of pathogens, modiﬁcation of
nanoparticles, antibiotic delivery and gene delivery). Then, we present aptamer-conjugated
nanocomplexes as the main and efﬁcient factor in gene delivery. Finally, we focus on the
targeted co-delivery of genes and drugs by nanocomplexes, as a new exciting approach for
cancer treatment in the decades ahead to meet our growing societal needs.
Keywords: aptamer, polyethyleneimine, hybrid nanocomplexes, antibiotic, targeting, gene
delivery systems
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adaptable for different disease applications. They have been
considered as a biological material and as a diagnostic and
therapeutic tool they have been used in the expansion of novel
drugs, drug delivery, gene delivery and antibiotic delivery
systems, etc.16–18 They are actually considered for targeting
an antibiotic and gene delivery system that controls the time
and place of drug release or inﬂuence on gene delivery.19
Aptamers have been effectively established against metal
ions, proteins, bacteria, viruses, and whole cells. High afﬁnity and speciﬁcity are some of their characteristics comparable with antibodies. Unlike antibodies, they are capable of
being selected under non-physiological conditions, such as
very high or low temperatures or pH.20 These features make
aptamers appropriate applicants for clinical use. A number of
aptamers have been designated for various diseases, eg, types
of cancers.21,22 Table 1 describes a list of the most common
differences between an antibody and aptamer.
Some published review articles have studied the role of
aptamers in the diagnosis and treatment of cancer and
disease.23–25 However, such work has been limited and
does not emphasize the signiﬁcant promise aptamers have
to revolutionize medicine. This review was carried out to
emphasize their importance in the future of antibiotic therapy, cancer diagnosis and treatment. Speciﬁcally, this review
summarizes recent studies on the use of aptamers in disease
diagnosis and treatment, antibiotic delivery and gene delivery, and also to review the use of aptamer-conjugated nanocomplexes in anti-cancer applications.26,27
Table 1 Different Properties Between Antibodies and Aptamers
Aptamer

Antibody

Unlimited shelf life (several months)

Limited shelf life (few months)

High tissue penetration (small size,

Low tissue penetration (large

3 nm)

size, 10–15 nm)

High speciﬁcity and afﬁnity

High speciﬁcity and afﬁnity

High stability in pH and temperature

Low stability in pH and
temperature

Low immunogenicity

High immunogenicity

Variety of modiﬁcation by diverse
molecules

Hard to be modiﬁed

Cost of production of aptamer is less
expensive

Cost of production of
antibody is expensive

Presence of nuclease susceptibility
(need for modiﬁcation)

Absence of nuclease
susceptibility
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Aptamers as Diagnostic and
Therapeutic Agents
Pathogenic diseases are some of the most prevalent diseases that threaten the lives of many people all over the
world, which have been created through various microorganisms. The inefﬁcient transfer of antibiotics to the site of
infection and side effects due to their great consumption
by the immune system, and also the slow rate of developing new and improved anti-pathogenic drugs, are important global issues that need to be solved now. The
development of targeted therapies and proprietary diagnostic methods for diseases caused by pathogens, infections
and cancers is increasing. Targeted therapies have been
developed based on aptamers in recent years to overcome
these problems. Studies have been conducted on the use of
aptamers in the ﬁeld of diagnosis as well as targeted and
early therapies.28,29
As just one example, Francisella tularensis, an aerobe
bacterium, acts as a pathogenic agent and causes tularemia
in men and animals. This pathogen is considered as one of
the most signiﬁcant biological threats that has a high
degree of infectiousness, and a high capacity for disease
and mortality (30%-60% were reported in the preantibiotic area). In fact, it is possible to point out the
importance of the use of aptamers in the detection of the
biological ﬁght factor.30–32
An outstanding study generated aptamers (ssDNA) that
bind to the F. tularensis subspecies. In this study, a set that
contained 25 aptamers was isolated to speciﬁcally conjugate to the F. tularensis subspecies. Investigation into these
aptamers under certain conditions indicated that the aptamer complex conjugated to the tularemia antigen speciﬁcally, which enabled it to be used as diagnostic tool for
a biological ﬁght factor like F. tularensis.33–35
Another prevalent bacterial infection is caused by
Vibrio parahemolyticus and Staphylococcus aureus
(S. aureus). V. parahaemolyticus is a common cause of
intestinal illness after eating uncooked or raw seafood and
as it is in environmental waters. Symptoms of
V. parahaemolyticus are watery diarrhea, abdominal pain,
vomiting, nausea, fever, headache, and bloody diarrhea.
As a result, providing a method for its rapid and speciﬁc
detection is of the utmost importance.36,37
The ﬁrst whole-bacterium SELEX application to reconnoiter speciﬁc DNA aptamers was reported for
V. parahemolyticus. This strategy was used for a set of
FAM-labeled ssDNA molecules to identify the aptamers

International Journal of Nanomedicine 2020:15

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 134.48.158.76 on 25-Aug-2021
For personal use only.

Dovepress

that were speciﬁcally attached to V. parahemolyticus. This
identiﬁcation was done by the use of ﬂow cytometric
analysis. According to the obtained results, the aptamer
A3P indicated great binding afﬁnity (76%) to
V. parahemolyticus. This feature can be used for the detection of this bacterium even in food. Moreover, linking of
this sequence to magnetic nanoparticles (NPs) and conjugating it to sensitive detection probes can help to control
food safety.34,38
S. aureus is a round-shaped bacterium that can be
pathogenic and a menace to human health.39 Evaluating
S. aureus through a molecular recognition procedure with
aptamer detectors is extremely effective.40 Moreover,
enrichment and separation by magnetic particles and ﬂuorescence detection by gold nanoclusters (AuNCs) are
powerful tools for their evaluation because of their controllability and high sensitivity.41,42 In one study, Cheng
et al indicated a new method for the detection of S. aureus
in which recognition molecules, such as an aptamer, and
antibiotic were combined together. In this study, S. aureus
was quantiﬁed via the use of aptamer-coated magnetic
beads (Apt-MB) and Vancomycin (Van)-functionalized
ﬂuorescent nanoclusters (AuNCs@Van, with 2.0±0.6 nm)
in a mixture of other non-targeted bacteria and was also
detected in authentic samples including milk and human
serum.
After the synthesis of AuNCs@Van, its formation was
conﬁrmed by a transmission electron microscope (TEM)
and X-ray photoelectron spectroscopy (XPS). Since the
nanoprobes should be chemically and photochemically
stable, the stability of AuNCs@Van nanoprobes was
checked by UV illumination and the surrounding buffer.
Observations showed the successful synthesis and stability
of AuNCs@Van in various buffers and pH levels. Next,
the attachment of AuNCs@Van to the bacteria was proved
by ﬂuorescence microscopy and TEM. The detection of
S. aureus from complex samples and in authentic samples
was shown in the range of 32–108 CFU/mL and the limit
of detection (LOD) of 16 CFU/mL. Finally, it was conﬁrmed that the magnetic beads coated by the aptamer and
ﬂuorescent AuNCs covered by the antibiotic could be used
to quantify and detect bacteria from complex samples in
a binary assessment process. Apt-MBs and AuNCs@Van
dual recognition could detect S. aureus in milk and human
serum as authentic samples with high efﬁciency (96.94%
to 101.24%, respectively), so that it could be applied for
the assessment of food contamination related to S. aureus
bacterium and infection disease recognition43 (Figure 1).
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This strategy has several advantages over previous
studies, including it is easy-to-use and it is much cheaper
to synthesize AuNCs @ Van than antibodies, and has a
bacterial detection at concentrations as low as a ppm concentrations. However, from the limitations of this study,
absent the pre-separation for targeting bacteria from other
interfering components prior to ﬂuorescence measurements, it is not likely to yield a real result.
Also in another study, Charoenphol et al applied a cellspeciﬁc aptamer-DNA nanostructure system for treatment
purposes.44 DNA nanostructures have been vastly used in
various applications because of their special characteristics
such as programmability, uniform structures, biocompatibility and biodegradability. For example, DNA nanostructures have the ability to carry several therapeutic cargos
(such as aptamers, small interfering RNA (siRNA), etc.)
without any chemical correction. In this study, they
merged AS1411 aptamers into DNA pyramids and
observed selective inhibition in the growth of Hela cells
(a kind of cancer cell). In addition, it was found that
aptamer-displaying DNA pyramids were more stable to
nucleus decadence than single-stranded aptamers.
However, in this study, a single cargo type was indicated,
but DNA can be used in a combination therapy.44 For
example, a combination of chemotherapy and small RNAbased therapy (siRNA) is an example of these combination
therapies. It is assumed that chemotherapy and siRNA can
be delivered simultaneously to the same tumor cell to exert
their synergistic effect, however, the development of these
systems through systemic administration is still facing
challenges.45
With the development of nanomedicine and aptamer
selection methods, aptamer-functionalized NPs have
opened a new direction to diagnostic and therapeutic applications. There have been many reports about the use of
NP-aptamer conjugates for the delivery of NPs into cancer
cells. Early diagnosis of cancer is a challenge for effective
treatment and aptamers attached to NPs are considered as
highly promising molecular detectors in this ﬁeld worthy
of more attention and clinical trials.46,47
Magnetic NPs associated with ﬂuorescence moieties
could detect and elicit exfoliated tumor cells. Recently,
a study based on the application of aptamer-conjugated
dual NPs with two features (including magnetism and
ﬂuorescence) to detect and elicit exfoliated tumor cells
which are in the blood was conducted. Due to the low
numbers of these cells that were surrounded by various
other cells, an approach that created selective extraction
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Figure 1 Schematic illustration of the recognition process of S. aureus using a AuNCs@Van and Apt-MB (I) dual recognition assay, and the characterization (II) (A–F) represents the
optical, ﬂuorescence and transmission electron microscopy characterization of this synthesized particle. The ﬁgure was reprinted with permission from Cheng D, Yu M, Fu F, et al. Dual
recognition strategy for speciﬁc and sensitive detection of bacteria using aptamer-coated magnetic beads and antibiotic-capped gold nanoclusters. Analytical Chemistry. 2016;88(1):820–825.
Copyright © 2016 American Chemical Society.43

and sensitive detection was required. For this purpose, the
researchers used aptamer-conjugated NPs (ACNPs) with
ﬂuorescent NPs (FNPs) to extract and detect tumor cells.
When the various parameters were combined, the most
selective and sensitive ACNP system was speciﬁed. This
approach can be adjusted for a variety of cancers to determine the possible ACNPs for the recognition and extraction of cancer cells.41 In another study, aptamers
conjugated with magnetic NPs (ACMNPs) were utilized
by Bamrungsap et al to diagnose cancer cells.48 The ability
to detect at least 10 cancer cells in 250 µL of the cancer
cell sample is a feature of this biosensor. ACMNPs utilize
the features of aptamers to bind speciﬁcally to target
cancer cells, and the broad surface of these NPs provides
for the binding of several aptamers. In addition, a set of
ACMNPs can be used to accurately detect molecules at the
molecular and cellular level and detect them in fetal
bovine serum, human plasma and whole blood.
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Breast cancer is a type of severe form of cancer and
the second reason of death in women today. Investigations
showed that relatively large numbers of circulating tumor
cells (CTCs) were detected in the peripheral blood cells of
people who suffer from breast cancer, so the diagnosis of blood
CTCs is a hopeful method for the detection and determination
of breast cancer cells. There are two cancer cells which cause
breast cancer: human epidermal growth factor receptor 2
(HER2) and Mucin 1 (MUC1). HER2 and MUC1 are overexpressed in 15–20% and 90% of breast cancer patients,
respectively. So, through the use of multi-target methods with
HER2 and MUC1 probes, CTCs of breast cancer could be
detected with high accuracy and precision. NPs have been used
in various studies for the identiﬁcation of breast cancer due to
their advantages such as easy surface modiﬁcation, etc.49–51
In a distinct study, a dual aptamer system including HER2
and MUC1 modiﬁed-SiNP (Dual-SiNP) for the diagnosis of
breast cancer was considered. The dual aptamer approach
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provided the ﬁrst and wide detection and diagnosis system
for HER2 and MUC1 breast cancer cells. This synthesized
probe was assessed by some techniques such as ﬂuorescence
spectroscopy, dynamic light scattering and UV-Vis spectroscopy. The application of this system was limited to in vitro
systems because of several difﬁculties of in vivo systems
including: inconsistency of nucleic acids in the blood, the
decadence of ﬂuorescence signals of the probes in blood, NPs
with short half-life in blood ﬂow, etc.52,53
Heavy metals are an important environmental contaminant. For example, the mercuric ion (Hg2+) is a toxic nonbiodegradable heavy metal in which its accumulation in an
organism will have irreparable effects even death. There are
many analytical methods for measuring Hg2+ such as UV-Vis
spectroscopy, atomic absorption/emission spectroscopy
(AAS/AES) and X-ray absorption spectroscopy. These methods require expensive and complicated instruments, so there
is an intense inclination to develop new methods with greater
efﬁciency for Hg2+ ions detection. An effective method for
the recognition of Hg2+ions requires the application of oligonucleotides. In order to form thymine- Hg2+-thymine complexes (T-Hg2+-T), Hg2+ ions interact with thymine bases and
also could make an aptamer-thymine- Hg2+-thymine nanocomplex for biological applications.54–56
From another perspective, detecting Hg2+ ions has been
considered as a strategic method by designing a mercury DNA
(MSD) functionalized gold nanoparticle (AuNPs) for Hg2+ ion
detection. The mechanism for this process was based on
a T-Hg2+-T complex and suppressing the ﬂuorescence feature
of AuNPs. AuNPs-MSD probes were formed through conjugation of MSDs labeled with ﬂuorescein (FAM) and AuNPs
by Au-S bonds. Hg2+ detection was investigated by changing
ﬂuorescence signals. Also, this method showed high selectivity for Hg2+ between additional metal cations (such as Fe3+,
Ca2+ and Mg2+, Cr3+, Mn2+, Cu2+, Ni2+, Pb2+ and Co2+).
Further, this method could be used for Hg2+ detection in
aqueous solutions. In addition, this method could be applied
for detecting heavy metallic ions in body ﬂuids by conjugating
them with an aptamer and formation of aptamer
nanocomplexes.57–59 Table 2 describes the types of aptamerbased nanostructures for applications in diagnostics with their
advantages and limitations.

Aptamers as Targeting Components
for Antibiotic Delivery Systems
Antibiotic delivery aptamers have been illustrated in a number
of reports.65–67 Aptamers were used for immobilizing
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antibiotic molecules instead of targeting them. For example,
a nanocarrier for neomycin (aminoglycoside antibiotic) was
developed by aptamers for delivery purposes, wherein aptamers immobilize antibiotic molecules via afﬁnity binding.
Mesoporous silica NPs (MSNs) could be an appropriate nanocarrier in stimuli-responsive drug delivery systems.68–70
In a study, an aptamer-gate mechanism was designed
using a binding aptamer (AS1411). By converting aptamer
sequences to the hairpin structure, a S. aureus (bacterium)
speciﬁc molecular gate was gained. The interaction
between S. aureus surface antigens and aptamer succession disrupted the aptamer structure. Increasing the rate of
ﬂuorescence depended on the presence of the objective. In
this study, SA20hp was selected as a molecular gate aptamer because of its high ﬂuorescence peak response. The
destruction mechanism of the pathogenic agent was as
follows: Van (antibiotic) was absorbed into the pores of
MSNs and covered with the SA20hp molecule. When the
NPs conjugated to surface of S. aureus cells through
aptamer successions, the Van antibiotic was released to
destroy the bacteria. These aptamer-gated silica NPs provided for a control of antibiotic dosage and unique internal
release, and then, enabled the possibility of using stronger
therapeutic compounds.71,72 In addition, several presitigous articles address different analytical methods and biosensors with capping different types of metal nanoparticles
with biomolecules, as well as porous nanomaterials
(Figure 2).73

Aptamers as Targeting Components
of Gene Delivery Systems
Nowadays, scientists are looking for new methods to treat
and control diseases such as gene therapy. Gene therapy is
the treatment process of nucleic acid transference into the
patient’s cells by viral or non-viral carriers to repair faulty
genes or provide further biological functions. In this
approach, genes and nucleic acids including plasmid
DNA (pDNA), anti-micro RNA (miRNA) oligonucleotides or siRNA are used. For nucleic acids, physical properties, such as negative charges, limit their binding to the
cell surface and inactive diffusion through the cell membrane. Therefore, the delivery procedure is the single signiﬁcant and difﬁcult challenge in gene and nucleic acid
therapy. Although gene delivery through viral vectors is
well known, many drawbacks (such as irregular cytotoxicity, etc.) limit their clinical usage. In contrast, non-viral
vectors provide many advantages such as low toxicity, no
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Table 2 Types of Aptamer-Based Nanostructures in Diagnostics with Their Advantages and Limitations
Aptamer-Based

Size of

Detection

Nanostructures

Nanostructures

Methods

Au NPs/

500 nm

Graphene (Au

LOD

Advantages

Limitations

Ref

Colorimetric

0.01–0.5 μM

Detection of various

Investigation of other

60

detection

and

targets by this aptamer,

lengths of aptamers

0.01–1.0 μg/L

rapid colorimetric assay,
design of speciﬁc aptamer

1.95 μg/·mL

Successful detection of
murine IL-6 (in the

Low sensitiv-ity, more
work is needed to

μg·mL−1 range) in buffers

increase the sensitivity

and a biological sample
matrix

to detect IL-6 in healthy
serum/plasma
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NPs/Gr)

Anti-IL-6
Aptamer-AuNPs

15 and 50nm

Colorimetric
detection

Graphene

2–3 nm size of

Electrochemical

Detect PSA in human

Using the three

quantum dots

GQDs, 2nm size

impedance

blood serum with high

analytical methods from

(GQDs)
-gold nanorods

of AuNRs

spectroscopy
(EIS), cyclic

sensitivity and
repeatability,

this study to measure
the signal at the same

voltammetry,

stability, cost effectiveness

time, but can also be

(AuNRs)

0.14 ng/mL

200 nm

-

62

used for better
measurement

differential pulse
voltammetry
Apt-Fe3O4
@mTiO2

61

10 to 2000
CFU/mL

Rapid and sensitive
detection of pathogenic

Although both systems
exhibit effective

bacteria, high selectivity

monitoring and high

and strong afﬁnity of
aptamers

sensitivity, the expensive
cost of detection limits

63

their widespread use
MNPs-speciﬁc

20nm size of

Colorimetric

7.5×105

Use of speciﬁc aptamers,

Low LOD, need to

aptamer

Fe3O4 MNPs

detection

CFU/mL

easy separation, low cost

enhance the LOD and to

64

increase the crossreactiv- ity to other
pathogens

infective danger, ﬂexibility and capability of production
and modiﬁcation. Non-viral vectors (including liposomes,
cationic polymers, cationic lipids, peptides and dendrimers) are known for their applications in gene delivery.
Additionally, due to the success of gene therapy dependent

on the efﬁcient delivery of genes to speciﬁc cells (targeted
gene delivery), today, many targeting ligands (such as
antibodies, nanobodies, peptides and aptamers) have been
used for gene and drug transfer into particular cancer
cells.74–78

Figure 2 AuNPs-aptamer was capped on the MSA surface due to the binding reaction of ATP aptamer to the adenosine molecule. The delivery of the entrapped guest
(ﬂuorescein) was selectively triggered by an effective displacement reaction in the presence of the target molecule (ATP). Reprinted with permission from Zhu CL, Lu CH,
Song XY, Yang HH, Wang XR. Bioresponsive controlled release using mesoporous silica nanoparticles capped with aptamer-based molecular gate. J Am Chem Soc. 2011;133
(5):1278-1281. Copyright (2020) American Chemical Society.73
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Some cancer cells, such as melanoma (skin cancer),
cannot be easily treated in the clinic today because of
their resistance to radiotherapy, insigniﬁcant diagnosis
and numerous speed of deformation (the BRAF gene
mutation in many melanomas makes treatment difﬁcult).
Gene therapy is a sufﬁcient treatment for melanoma
versus common treatments (such as radiation therapy)
because of its high speciﬁcity and low toxicity.
Therefore, gene therapy using SiRNA (small RNAi)
which targets the BRAF gene could be an effective treatment method for melanoma.79,80
A new strategy suggested by Liyu et al in which nucleolin-targeting liposomes were constructed to deliver SiBraf
(anti-BRAF SiRNA) could be promising for therapeutic purposes (Figure 3). AS1411 is an aptamer with a speciﬁc binding ability to nucleolin. AS1411 was tagged to polyethylene
glycosylated (PEGylated) (PEGylated) liposomes (ASLP)
that acted as a targeting probe. AS1411ePEG-liposomes
(ASLP) and SiRNA were conjugated to each other, electrostatically, to create a ASLP/siRNA complex. Observations
indicated that the AS1411 aptamer conjugated liposomes,
targeted speciﬁc cancer cells (A375) and showed considerable silencing activity in this cell line. So, the application of

Rabiee et al

ASLP and AS411 aptamers to deliver siRNA showed high
efﬁciency for melanoma therapy and should be further studied in clinical trials.80,81

Gene Delivery Through PEI-Based
Vectors
Polyethyleneimine (PEI), a polycation molecule with the
ability to compress DNA (through electrostatic interactions between anionic phosphate of nucleic acids and
primary amines of PEI) into NPs and high transfection
efﬁciency during in vitro and vivo conditions, is a very
effective non-viral vector. PEI delivers NPs which contain
genes into the cytoplasm before degradation by some
enzymes (such as lysosomal enzymes) through a proton
sponge (proton buffering) mechanism. For PEIs, molecular
weight is so important because of its effect on transfection
efﬁcacy. The low molecular weight of PEIs represents low
cell toxicity and transfection efﬁcacy. For this matter,
scientists designed a kind of ligand-conjugated PEIsbased vector with low toxicity and great transfection efﬁcacy. Aptamers are the best option as functional targeting
ligands for speciﬁc targeting.83–86

Figure 3 Schematic representation of cationic nanoparticles for targeted delivery of siRNA-aptamer chimeras. Immobilization of preformed siRNA-aptamer chimeras onto
positively charged QD-PMAT-PEI nanoparticles. The aptamer block collapsed on the carrier results in reduced binding activity. Two-step immobilization of chimeras on a
cationic nanoparticle surface. siRNA molecules with a thiol-reactive terminal group are ﬁrst adsorbed on the QD-PMAT-PEI surface to reduce the positive charge;
subsequently aptamers with a single thiol group are brought in to form siRNA-aptamer chimeras on the nanoparticle surface. Adapted with permission from Bagalkot V, Gao
X. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano. 2011;5(10):8131-8139.82,138 Copyright (2011)
American Chemical Society.
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Targeted Gene Delivery by Aptamer-PEI
Nanocomplexes
Non-speciﬁc binding of pDNA/PEI complexes to proteoglycans on cell membranes would lead to non-competence
for gene transfer to speciﬁc cells. An outstanding research
group developed some approaches in which pDNA/PEI
complexes were covered with polyadenylic acid (PolyA)
as a polynucleotide. Aptamer-based molecular assessments
illustrated that these aptamer-coated complexes could
enter cells via a cellular uptake process. In addition, studies showed that MUC1 would be adequate for tumor
targeting. Therefore, Kurosaki et al synthesized pDNA/
PEI/MUC1 complexes for the treatment of cancer cells
through targeted gene delivery. In this research, several
complexes at several weight ratios of pDNA/PEI/aptamer
were constructed. This experiment was done in vivo and
in vitro using a human and mice lung cancer cell line,
A549 cells. The efﬁciency of in vivo and in vitro transfections for various weight ratios of aptamer complexes was
investigated. The results indicated that for A549 cells with
the MUC1 cell surface protein, the use of the pDNA-based
aptamer complexes with weight ratios between pDNA,
PEI and MUC1 of 1:1:0.25, 1:1:0.5, 1:1:1 and 1:1:2
increased gene expression. Also, large amounts of the
MUC1 aptamer reduced aptamer-complex gene expression. It seems that robust anionic surface charges act on
cellular membranes and the backlash might be higher than
the binding strength of the MUC1 aptamer to MUC1.
In addition, results showed that the application of nonspeciﬁc aptamers reduced transgene expression. Besides,
studies have shown that the aptamer complex used for
tumor speciﬁc gene delivery, by simply changing aptamers, this complex could be used for other speciﬁc gene
delivery systems. The targeting and coating system may be
pioneering knowledge for cell speciﬁc gene delivery.87–89
Lymphocytes are the main cellular species in the lymph
modes. Special features of these cells (such as reintroduction into the body, mobility and distribution all
over the body) provide for gene therapy for genetic and
pathogenic diseases. Hamedani et al designed a novel complex in which the sgc-8c aptamer was non-covalently conjugated to the PEI polycation to raise transfection efﬁciency
of the targeted gene delivery of pDNA into MOLT-4 cells. In
general, the efﬁcient transfection of pDNA via a vector will
be obtained when there is an equilibrium between the condensation and fast diffusion of pDNA in the cytoplasm. For
measuring the condensation of DNA and PEI-aptamer
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conjugation, ethidium bromide (EtBr) molecules were
used. These molecules showed ﬂuorescence until they
were accommodated in double-stranded nucleic acids. By
adding PEI to the pDNA/EtBr solution and condensation of
pDNA by PEI, because of the release of some accommodated EtBrs molecules from pDNA and negligible interactions between them (because of the structural transformation
of pDNA from a helix to a globular form), ﬂuorescence
intensity decreased.90–93
Moreover, the addition of the aptamer did not have any
effect on the ﬂuorescence and shape of the curves. Particle
size and zeta potential were additional measurable features
in this study. It is necessary to distinguish carriers according
to these two factors because nanoparticle size and their surface charge affect gene delivery efﬁciency. By using small
particles of ≤ 500 nm size, faster and easier cellular uptake
as well as transfection efﬁcacy occurred. Generally, in this
study, the addition of a 10% w/w aptamer (with a negative
charge) to a 10kDa PEI-pDNA polyplex caused an increase
in particle size and decrease in zeta potential (reduced net
positive surface charge). Positive surface charges of PEI
interacted with cell membrane negative charges and caused
PEI to become cytotoxic and instable in the cell membrane.
In addition, the cytotoxicity of the pDNA-based aptamer
complexes was determined for a protein tyrosine kinase 7
(PTK7)-positive and -negative, MOLT-4 (human, peripheral
blood, leukemia, T cells) and U266 cell lines, respectively.
All vectors represented low toxicity, however, by increasing
PEI/pDNA proportions, toxicity increased and the presence
of the aptamer did not have a signiﬁcant effect on cytotoxicity. Researchers have used many strategies to treat lymphocytes, such as treating them with large amounts of genetic
material but because these cells are resistant to most gene
transfection systems, association of vectors increased cytotoxicity. One study used targeting aptamer PEI-based vectors to increase transfection efﬁcacy. The evaluation of
transfection efﬁciency and targeted delivery of PEIaptamers to PTK7 receptors in MOLT-4 and U266 cell
lines showed that in MOLT-4 cells with PTK7 receptors,
the PEI/pDNA polyplexes and sgc-8c aptamer conjugation,
increased transfection efﬁcacy. Moreover, information
showed that the conjugation of a nonspeciﬁc aptamer to
PEI/pDNA polyplexes, prevented luciferase gene expression. Finally, the results obtained in this study showed that
a cell speciﬁc sgc-8c aptamer which tagged the PEI vector
through electrostatic interaction, could increase transfection
efﬁcacy. In addition, the sgc-8c aptamer kept its conformation after electrostatic binding to PEI and retained speciﬁcity
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and dependency of PTK7 to bind to MOLT-4 cells,
selectively.94–97
Also in a recent study, a new EpCAM Aptamer -PEIsiRNA nanocomplex (PEI-EpApt-SiEP) was designed for
EpCAM (epithelial cell adhesion molecule, with features
such as overexpression in solid tumors and being
a diagnostic marker for various cancer cells) targeting
(Figure 4). In recent years, RNA and DNA aptamers instead
of antibodies, were developed against EpCAM by the use of
SELEX technologies. Moreover, siRNA (operating within
RNA interference (RNAi)) was considered as an appropriate
nucleic acid for targeted gene therapy especially in humans.
In this study, to prepare an optimal PEI nanocore, sodium
citrate was used for stabilizing its charge. For nanocomplex
synthesis, at ﬁrst, siRNA was added to the PEI nanocore and
after, the aptamer was added to create a nanocomplex with
EpCAM detection ability. Since the exact concentration of
the aptamer (200 nM) and siRNA was capable of saturating
the PEI-citrate nanosphere, the optimized concentration of
SiEp and EpApt were mixed with PEI-citrate for constructing a novel PEI-EpApt-SiEp nanocomplex. As higher concentrations of PEI leads to higher cell toxicity (ie, 3 µg/mL),
0.3 µg/mL of PEI was used to functionalize the aptamer and
siRNA. Zeta potential and particle size of the PEI nanocore
and nanocomplex were investigated. To evaluate the
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application of this nanocomplex for in vivo systems, serum
was shown to inﬂuence the size and charge of the nanocomplex as determined in RPMI.
The results indicated that there was a negligible difference in size and charge of nanocomplexes in the presence
and absence of serum. Cellular uptake and cell binding of
the complex (PEI-EpApt-SiEp) were investigated in breast
cancer and WERI-Rb1 cell lines. Observations showed
that the expression of EpCAM proteins and aptamer binding were higher in MCF-7 compared to WERI-Rb1 cells.
Concerning cellular uptake for both of these cells, binding
of cells to PEI-EpApt-SiEp caused a boost of the intensity
of the ﬂuorescent spectra in comparison with the EpApt
alone. The greater binding of the PEI-EpApt-SiEp nanocomplex compared to EpApt and no connection of the
ScrApt-nanocomplex or ScrApt to both cell lines, showed
cell speciﬁcity of the EpCAM aptamer. The EpCAM silencing effect using the PEI-EpApt-SiEp nanocomplex was
evaluated by checking the protein and mRNA amount by
Western blotting and qPCR techniques, respectively. In
treating MCF-7 and WERI-Rb1 with PEI-EpApt-SiEp,
down regulation of the EpCAM gene was higher than the
SiEp treatment (64%, 72% versus 56%, 62%, respectively). Moreover, PEI-ScrApt-SiEp and PEI alone treated
cells, did not illustrate any EpCAM silencing. The

Figure 4 Schematic of the newly synthesized aptamer-PEI-siRNA nanocomplex (PEI-EpApt-SiEP) and its function to silence the target gene and decrease cell proliferation. The ﬁgure
was reproduced from Subramanian N, Kanwar JR, Athalya P, et al. EpCAM aptamer mediated cancer cell speciﬁc delivery of EpCAM siRNA using polymeric nanocomplex. J Biomed Sci.
2015;22(1):4. Copyright © Subramanian et al; licensee BioMed Central. 2015. Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0).98
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EpCAM protein expression and mRNA levels did not
change substantially compared to untreated cells. For
MCF-7 and WERI-Rb1 treated with PEI-EpApt, EpCAM
levels were reduced by 38% and 52%, respectively.98
Based on the previously obtained results, although
EpCAM silencing in this method was less than by
siRNA delivery via a targeted antibody, this nanocomplex
demonstrated more functional activity and EpApt in this
structure induced cytotoxicity with overexpressed levels of
EpCAM. This novel nanocomplex included an aptamer
and siRNA and effectively targeted EpCAM positive
cells and suitable gene silencing activity that can be
applied for in vivo systems.70,99

Targeted Gene Delivery Using
Aptamer-Conjugated Copolymers
Bcl-xL (B-cell lymphoma-extra large) is a transmembrane
molecule in the mitochondria. It is a kind of protein with
anti-apoptosis properties which causes programmed cell
death by preventing the release of mitochondrial content.
In many cases, the overexpression of Bcl-xL protein leads
to lung cancer. Gene and drug delivery are effective treatment methods for lung cancer due to some features of lung
cells (such as low enzymatic activity and wide surface
area). However, plenty of research has been conducted
concerning PEI derivative applications for nucleic acid
transference to the lung, but more attempts should be
made for introducing new strategies based on cationic polymer vectors for more efﬁcient gene delivery systems.100–102
Recently, a novel carrier based on a poly(L-lysine)
(PLL)-alkyl-PEI copolymer was designed and the effect of
aptamer conjugation on short hairpin RNA (shRNA) plasmid gene delivery efﬁciency was investigated for gene
delivery of this modiﬁed vector to lung cancer cells.
Beside PEI, PLL is a cationic polymer non-viral vector
that can be used for most gene delivery purposes. Both of
these polymers have disadvantages which limit their use as
a vector for gene transference. In this research, a novel
copolymer vector including PEI (with DNA condensation
ability) and PLL (biodegradable) was designed to overcome
deﬁciencies of these polymers. For the preparation of
a copolymer, at the beginning, an alkylcarboxylate (6-bromohexanoic acid) was coupled to PLL at three molar ratios.
Next, PEI was conjugated to PLL (via hexanoate linker) to
produce PLL-hexanoate-50%-PEI (PLPE36%) copolymers
and PLL-hexanoate-10%-PEI (PLPE8%). Vectors have
many roles in gene delivery (such as carrying nucleic acid
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cargos and also their condensation and protection from
extracellular degradation), so their optimal size and charge
density are crucial for all medical applications.
These two properties were measured via laser Doppler
velocimeter and DLS. The results showed that after this
successful coupling (the exact conjugation of PEI to alkylcarboxylated-PLL), the positive surface charge and nanoparticle size increased. The buffering capacity of vectors is
crucial in polycation mediated gene delivery. The investigations illustrated that unlike PLL with a weak buffering
capacity, copolymers had suitable buffering capacity,
almost the same as the PEI polycation. Moreover, ﬂuorescence suppression analysis with the EtBr molecule indicated that the modiﬁed polymers could be capable of
condensing DNA at the determined C/P ratio, above 0.5.
The obtained information showed that electrostatic interactions which come from the attachment of the AS1411
aptamer to the copolymer that has been modiﬁed, could
enhance transfection efﬁciency with an insigniﬁcant consequence on charge density and size. Finally, the aptamerconjugated at the determined C/P was selected for shRNA
delivery to silence human Bcl-xL gene expression in A549
cells. Protein expression and mRNA levels of Bcl-xL
substantially decreased after shRNA plasmid transfection
by aptamer-vector system against the Bcl-xL gene. So, this
study suggested an efﬁcient novel vector (apt-PLPE8%)
for targeted non-viral gene delivery in lung cancer and
pulmonary systems.77–79,103

Targeted Gene Delivery Using Aptamer
Modiﬁed Carbon Nanotubes
As we know, shRNA and siRNA can be used for therapeutic purposes and there are two signiﬁcant challenges in
targeted gene delivery including low toxicity and great
transfection efﬁciency of the synthesized vectors. PEI is
a kind of polycation and an effective non-viral vector with
buffering capacity. In reality, branched PEI consists of
primary, secondary and tertiary amines, so it can be protonated and provide a buffer. Also, the molecular weight of
PEI plays a major role in transfection efﬁciency of this
molecule. As the PEI molecular weight increases, the
growth of a positive surface charge and reduction of
transfection efﬁciency will result. Alkylcarboxylation of
PEI improves transfection efﬁciency.104–107
Single-walled carbon nanotubes (SWNTs) can be used
in delivery systems due to its easy passage through the
plasma membrane. Since SWNTs have poor solubility,
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they cannot be used as an efﬁcient carrier. By inducing
positive charges onto a SWNT surface, in addition to simplifying solubility in water, they can connect to molecules
including DNA and siRNA with a negative charge.
Generally, conjugation of polycations as PEI is an effective
strategy to enhance DNA condensation of CNTs.108,109
As an example, a new system based on single-walled
nanotubes functionalized with piperazine-PEI and an aptamer for siRNA transference into breast cancer cells proved
that gene delivery could be used to diagnose cancer cell
presence. EpCAM is a membrane protein which can be
overexpressed in tumors and is recognized as a promising
marker for cancer stem cells; it can be a cancer stem cell
marker (CSCs). In the present study, PEI-piperazine was
attached to functionalized SWNTs. Afterwards, SWNT-PEIpiperazine NPs tagged the EpCAM aptamer. For conjugation of SWNTs to PEI, surface carbons on SWNTs were
oxidated to become COOH. So, this functional group could
conjugate PEI amine groups via formation of amide bonds.
To have an effective gene carrier, it is necessary to deliver
therapeutic mediators to their speciﬁc cells, selectively. For
this purpose, a targeting aptamer was used. Prior studies
showed that conjugation between an aptamer and NPs
increased delivery efﬁciency. So, a SWNT-PEI-piperazine
/DNA complex was bound to the EpDT3 aptamer.
Observations showed that transfection efﬁciency largely
increased. As a result, in this study, the effect of the novel
SWNT-PEI-piperazine NP to transfer BCL91 siRNA to
EpCAM cells was assessed. This type of vector-aptamer
derivative could increase DNA transfection efﬁciently. This
strategy also could be used for breast cancer treatment by
gene therapy.110–112
In a similar study, a novel targeted nanocomplex inclusive of PEI-CNT conjugated to the 5TR1 aptamer created for
the speciﬁc delivery of Bcl-xL shRNA for breast cancer cell
treatment.113 For the ﬁrst step, functionalized single-walled
SWCNs were synthesized. Because of negligible solubility
of SWCNs in aqueous solutions, they were oxidized at the
edge carboxylate groups via concentrated nitric acid solutions. Also, SWNTs and poly(ethylene glycol) (PEG)/PEI
were conjugated covalently to prevent aggregation in biological environments and improve their DNA condensation
ability. PEI (10kDa) was modiﬁed by various kinds of
bromo-alkylcarboxylic acids. In reality, PEI primary amine
alkylcarboxylation created PEI vectors with increased lipophilicity which caused a reduction in PEI toxicity and
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incremental increases in gene delivery efﬁcacy. To conjugate
PEI and modiﬁed-PEI to SWCNT-PEG, -COOH groups of
PEG were covalently bound to primary amines of PEI.
Formation of modiﬁed SWCNT and PEI was veriﬁed by IR
spectroscopy. The existence of strong absorption bands at
1645.66 cm−1 and 1657 cm−1 veriﬁed the existence of amide
bonds between SWCNT-COOH/PEG and amide conjugated
PEI/SWCNT-COOH-PEG. To evaluate pDNA condensation, ﬂuorescence intensity of the NPs were investigated in
the vicinity of pDNA and EtBr. A reduction in ﬂuorescence
intensity proved the condensation of pDNA through
SWCNT-PEG-PEI NPs. Evaluation of the results showed
that SWNT-PEG-PEI compared with SWNT-PEG-n-x%PEI (with a lower primary amine percent) and SWCNTPEG modiﬁed PEI could condense pDNA to lower C/P ratios
and in sizes lesser than 150 nm with zeta potentials between
6.3–30.8 mV. This method enables the study of the binding
ability of different forms of genetic materials to the different
conjugates of MWCNTs, and also the morphology of the
synthesized MWCNTs is an important parameter in the binding ability process (Figure 5).114
Since targeted gene delivery through aptamerfunctionalized NPs improves the efﬁcacy of the antitumor
treatment, targeted gene delivery of this NP was done with
the 5TR1 aptamer. Image analysis demonstrated that about
half of the aptamers were covalently bound to the NPs and
the remainder of aptamers were conjugated electrostatically
onto the surface of NPs. Cytotoxicity evaluation of
the polyplexes with and without aptamers in MCF-7
(MUC1+) and MDA-MB231 (MUC1-) via MTT colorimetric testing illustrated no toxicity in these cells. The
evaluation of polyplex transfection efﬁciencies using
Renilla luciferase showed SWCNT-PEG-10–10%-PEI with
a maximum transfection efﬁcacy at a C/P ratio of 6. Finally,
a SWCNT-PEG-10-10% vector was used to transfect plasmid Bcl-xL shRNA to MCF-7 and MDA-MB231 cells
(breast cancer cells) and assess the expression of the BclxL protein. The analysis of the obtained data indicated that
unlike MDA-MB231, transfection of MCF-7 cells with
plasmid Bcl-Xl shRNA by using a SWCNT-based aptamer,
decreased expression of Bcl-xL to 41%. So, this novel
nanocomplex including Bcl-Xl shRNA and a SWCNTbased aptamer, could be used to provoke cell death in the
MCF-7 cell line and, of course, MUC1 with low toxicity,
high selectively and great efﬁciency.115–117
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Figure 5 SEM images of carbon nanotube: DNA complexes formed at a 6:1 charge ratio: (A-C) MWNT-NH3 +:DNA; (D-F) SWNT-NH3 +:DNA. Reprinted with permission
from Singh R, Pantarotto D, McCarthy D, et al. Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: toward the construction of nanotube-based
gene delivery vectors. J Am Chem Soc. 2005;127(12):4388-4396.114,139 Copyright (2020) American Chemical Society.

A Novel Approach: Tumor-Targeted
Co-Delivery Systems via Aptamer Hybrid
Nanocomplexes
Cancer is the most prevalent disease throughout the
world. Many efforts have been used to treat it more
effectively and faster with less side effects. Although
chemotherapy is the most impressive and common
method to control cancer, many features (such as low
speciﬁcity, development of chemotherapeutic-resistant
cancer cells, etc.) that cause healthy cell cytotoxicity
and damaging side effects restrict its application.
Furthermore, in most cases, drug resistance generated
during the chemotherapy procedure leads to the eventual
failure of chemotherapy. In addition to overcoming these
difﬁculties, gene therapy can suppress oncogene activity,
increase the expression of tumor inhibitors and cause
immune responses against tumors.118,119

4248

Powered by TCPDF (www.tcpdf.org)

Dovepress

submit your manuscript | www.dovepress.com

DovePress

In recent years, many scholars have focused on a better
approach to combine chemotherapeutic drugs and nucleic
acids (such as siRNA and shRNA) and use their synergistic treatment effects to reduce the harmful side effects and
drug resistance of anti-cancer drugs. Designing a secure
and efﬁcient delivery system is a signiﬁcant challenge in
combinational drug and gene delivery.120,121
A novel system based on a SWCNT-PEG-10-10%-PEI
nanocomplex has been designed as an efﬁcient tumortargeted drug-gene delivery system by a AS1411 kind of
aptamer-modiﬁed with SWCNT-PEG-10-10%-PEI NPs
and the therapeutic efﬁcacy of Bcl-xL shRNA and doxorubicin (Dox, a chemotherapy medication used to treat
cancer) has been evaluated.122 Agarose gel electrophoresis
proved Apt-NPs conformation. Moreover, the obtained
results showed that 80% of the AS1411 aptamers were
covalently conjugated to the nano particles and the remainder of aptamers were electrostatically adsorbed onto their
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surface. The size and surface charge of the NPs and NPsaptamer were measured. The size of the modiﬁcation segment of the AS1411 aptamer, to be exact SWCNT-PEG
-10-10%-PEI, with pDNA was about 80±3 nm with
a surface charge of 18.15±2.14mv. After attachment, particle sizes increased to 109±1.13 nm and positive charges
reduced to 10.35±2.8 mv. Immunocytochemical analysis
and investigation of colored spots proved the existence of
nucleolin receptors on AGS cells (a human gastric adenocarcinoma cell-line) not L929 cells (NCTC clone 929
Clone of strain L). To demonstrate the main role of the
AS1411 aptamer in targeted cargo delivery of Apt-NP
complexes to cancer cells, AGS cells were saturated with
increased amounts of AS1411 aptamer due to the linkage
of the AS1411 aptamer with AGS cell nucleolin; this
aptamer uptake was very low. So, the results showed that
the aptamer had an efﬁcient effect on the tumor cells
against the modiﬁcation segment and proved to be the
main function of the aptamer in targeted drug/gene
delivery.
Bcl-xL suppression assessment was done through
Western blot analysis. Results indicated that in L929 cells
and AGS which were treated by the modiﬁed segment of
the aptamer, expression of the Bcl-xL protein was down
regulated by Bcl-xL shRNA. However, aptamer addition to
SWCNT-based shRNA in L929 cells did not have any
effect on Bcl-xL expression due to the lack of a nucleolin
receptor on L929 cells. So, all observations and results
conﬁrmed that functionalized-CNT-Apt polyplexes could
induce apoptosis in cancer cells by down-regulating the
Bcl-xL gene by the use of Bcl-xL shRNA. Loading of
Dox onto the SWCNT-PEG-10-10%-PE-aptamer-I/pBclxL shRNA surface was studied by assessing ﬂuorescence
intensity. Dox and the polyplexes combination reduced
ﬂuorescence intensity of free Dox at 595nm. Lastly, the
synergistic effects of Dox and Bcl-xL shRNA into AGS
cells was investigated via MTT testing. The combination of
Dox (100Nm)/SWCNT-based shRNA caused a decrease in
cell viability and increased cell death compared to Dox
only. So, this Dox/Bcl-xL shRNA co-delivery system with
high targeting ability because of the nano-needle structure
of SWCNTs and aptamer conjugation to the nucleolin
receptor on speciﬁc cells, caused a signiﬁcant anti-tumor
effect.122–124
miRNA, a small RNA molecule which plays a main
role in RNA silencing and gene expression regulation, can
be applied as a signiﬁcant therapeutic agent in tumor gene
therapy. MiR-34a, as a miRNA, is capable of inhibiting the
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appearance and advancement of cancer by reducing the
expression levels of protein-coding genes, such as Bcl-2,
survivin, etc. Also, in many types of research, it has been
proven that the co-delivery of chemotherapeutic agents
and miRNA through nanosystems play an effective therapeutic role both in vivo and in vitro. Scholars have
attempted to create stimuli-responsive delivery systems
which cause agglomeration of nanocarriers and quickly
release cargos at tumor sites and within tumor cells.125–127
A novel ATP-triggered nanosystem was developed
based on the ATP-responsive aptamer duplex (the aptamer
and its supplementary ss-DNA) designed with Dox and
a miR-34a co-delivery capacity using a PEI 25kDa vector
to prevent cell proliferation and migration. A hybridization
process was completed to convert the ATP aptamer and its
nucleic acid sequence to a duplex. After that, Dox was
loaded onto the duplex to create a Dox-Duplex. This
loading process was evaluated by ﬂuorescence spectrometry. Moreover, the ATP-responsive Dox release was completed in the vicinity of ATP. Results indicated that at
a high concentration of ATP, Dox was released from DoxDuplex. Generally, it was proven that Dox can be encapsulated and released through the duplex which will be
suitable for an ATP-responsive delivery system. A PEI
25kDa carrier was applied to condense the Dox-Duplex
and miR-34a and to co-deliver these two cargos. The
obtained optimal mass ratio for PEI/miR-34a and PEI/
Dox-Duplex was 1.5 and 2, respectively, so the ternary
nanocomplex with a mass ratio of 3:1.5:2 was used in the
following studies. The size and zeta potential of this optimal nanocomplex were 262.73±2.32 nm and +33.10±1.25
mv, respectively, which enabled the nanocomplex for cellular uptake and anti-tumor efﬁcacy. Assessment of ﬂuorescence intensity conﬁrmed intracellular miR-34a/Dox
release through PEI/Dox-Duplex/miR-34a because of the
high concentration of ATP in the cytosol. In addition, it
was proved which Dox was placed more in the nuclei and
that miR-34a was released in both the cytosol and nuclei.
Using MTT tests to assess cell proliferation inhibition
revealed that among various samples, such as PEI,
miR-34a, Dox-Duplex, the two PEI/Dox-Duplex/miR-34a
nanocomplexes indicated signiﬁcant inhibition of cell proliferation. Furthermore, live/dead tests were completed to
investigate the anti-proliferative effect. Observations proved
that the amount of dead cells in the PEI/Dox-Duplex/miR34a structure was more than the PEI/Dox-Duplex and PEI/
miR-34a. Actually, the synergistic effects of Dox/miR-34a
(due to the control of cancer cell proliferation through RNA
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interference of miR-34a and DNA intercalation of Dox) and
their fast release led to signiﬁcant cell proliferation inhibition.
Cell apoptosis assessment was studied by V-FITC/PI and PI
staining. In this case, PEI/Dox-Duplex/miR-34a nanocomplexes with a mass ratio of 3:1.5:2 and 4:1.5:2 showed high
cell apoptosis compared to single cargo structures. Also, cell
cycle prevention was evaluated. Results indicated that PEI/
Dox-Duplex/miR-34a compared to PEI/Dox-Duplex reduced
the G2 phase. So, it could be concluded that the antiproliferative effect of the PEI/Dox-Duplex/miR-34a nanocomplex is the result of cancer cell death and its cycle arrest
process. The effect of PEI/Dox-Duplex/miR-34a on the
expression level of speciﬁc proteins was investigated and
the results showed that Dox/miR-34a co-delivery could prevent Bcl-2 expression. Also, observations showed that the
ATP-responsive co-delivery system caused signiﬁcant cell
migration inhibition. As a result, the PEI/Dox-Duplex/miR34a nanocomplex with a synergistic effect and ATP-trigged
release of polyloads, could have effective anti-proliferative
and anti-migration efﬁcacy.128–130
In recent years, scholars have attempted to synthesize
novel nanosystems with the ability to target drug delivery
and control drug release. Polymers which are sensitive to
acidic surroundings and the proton sponge effect of lysosomes, speed up drug release and siRNA in tumor cells.131
For instance, a new graft polymeric micelle was synthesized as a carrier with duplex pH/redox sensitivity and
a AS1411 aptamer as a targeting ligand which was loaded
by gene and anticancer drugs. A chitosan-ss-PEI-urocanic
acid (CSO-ss-PEI-UA, (CPU)) graft polymer was synthesized by the acylation reaction between primary amines of
CSO or PEI and carboxyl groups of UA. Evaluation by
1
H NMR indicated that PEI was conjugated to CSO-ss and
UA was introduced into CP. In the CPU copolymer, CSO
was covalently attached to PEI through disulﬁde bonds to
reduce the positive surface charge of PEI and UA as
a hydrophobic agent and was added to a loading of Dox.
Moreover, to diminish the cytotoxicity of CPU micelles
and enhance its safety and efﬁciency as a vector, the
AS1411 aptamer (with speciﬁc binding to nucleolin and
high expression in the membrane of cancer cells such as
A549 cells) was added to the CPU micelle as a targeting
ligand. 1H NMR assessment showed that the CPU copolymer and AS1411 aptamer were covalently bound
together. TEM images of the AS1411-chitosan-sspolyethylenimine-urocanic acid (ACPU) micelle showed
particle sizes of 124.6±1.068 nm and an average zeta
potential 24.2±0.529 mV. Also, comparison of the CD
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spectra of the AS1411 aptamer and ACPU conﬁrmed that
the secondary structure of the AS1411 aptamer was preserved after attachment to a CPU micelle. In addition, the
low critical micelle concentration (CMC) of the ACPU
copolymer showed its self-assembly into a micelle which
was stable in vitro.
The pH/redox sensitivity of the ACPU micelle was
assayed by checking changes in micelle size during incubation in a weakly acidic phosphate-buffered saline (PBS) and
PBS plus GSH. With PBS (pH 7.4)+GSH and PBS (pH 5.1),
micelles inﬂated from 124 nm to 365.3 and 622.6 nm,
respectively. GSH caused an enhance drug and gene release
through destroying disulﬁde bonds. The Dox release from
Dox micelles and siRNA release from micelleplexes were
done in pH 5.3 PBS or with GSH 10Mm. These two factors
including protonation of UA in an acidic environment and
breaking of disulﬁde bonds in reductive conditions caused
the rapid release of Dox and siRNA.
Cellular uptake experiments illustrated that Dox and
siRNA were delivered to cells via micelles and then
released into the nucleus and cytoplasm. So, these
results proved the simultaneously delivery of drugs and
Dox into cells via the Dox-siRNA ACPU micelle system. To specify transfection efﬁciency of the siRNAACPU micelle, the toll-like receptor 4 (TLR4) mRNA
level and protein expression were evaluated by quantitative polymerase chain reaction (qPCR) and Western
blot techniques. After treatment with siRNA-ACPU
micelles, the mRNA level and protein expression of
TLR4 reduced. The antitumor efﬁcacy of the DoxsiRNA ACPU micelles was evaluated by a luc-A549
cell orthotopic tumor model. The results conﬁrmed that
the tumor inhibition from Dox-siRNA ACPU micelles
was very signiﬁcant. Moreover, Dox-siRNA ACPU
micelles down-regulated TLR4 protein levels to prevent
tumor invasion and improve tumor treatment efﬁcacy.
There is hope to use this novel co-deliver nanosystem in
other relevant diseases.57–59,132–134
Table 3 describes the types of aptamer-based structures
and their roles in gene delivery systems.

Conclusions and Future Outlook
The scientiﬁc society is looking for new techniques to
control, diagnose and treat diseases with gene therapy.
Gene therapy is the treatment process of nucleic acid
transference into the patient’s cells by viral or non-viral
carriers to remedy faulty genes or provide further biological functions. Pathogenic diseases are some of the
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Table 3 Types of Aptamer-Based Structures in Gene Delivery Systems
Aptamer-Based

Targeted Cells

Agents

Results

Ref

HepG2 cells

Tumor-suppressor

Increase the antitumor effect on liver cancer, decrease

135

gene of PTEN

disadvantages of naked Ad5-PTEN, selective and accurate

Structure
RNA aptamer
EpDT3
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target ability to EpCAM-positive HepG2 cells in vivo
PEI- sgc-8c

MOLT-4 cells and

aptamer

U266 cell lines

PDNA

A six- to eight-fold increase in transfection efﬁciency by

induced cytotoxicity due non-covalently conjugation to PEI
by electrostatic interactions
PEI/ARAD

HeLa cells

PDNA (p53)

Lower cell toxicity, high gene transfection efﬁciency

137

PEI-PEG-Wy5a

PC-3 prostate cancer

PDNA

PEI-PEG-Wy5a appropriate for prostate cancer-speciﬁc gene

138

Aptamer

cells, DU145 cells

delivery, Wy5a increase uptake of the complex into the
tumors than an AS1411 aptamer, formation of stable
complexes with pDNA

5TR1- aptamer

MCF-7 and MDA-

SWCNT-PEG-PEI

MB231 cell lines

Bcl-xL shRNA

8.5–10 fold improvement in transfection activity at C/P ratios

113

of 6 than PEI 25 kDa, low cytotoxicity and high gene delivery
efﬁciency

AS1411 aptamer-

AGS and L929 cells

pBcl-xL shRNA-DOX

SWNT-PEG-PEI
Scorpion stingers

This targeted delivery system inhibited the progress of

122

nucleolin-abundant gastric cancer cells with high selectivity
SK-BR-3 cells, MDA-

DNA nano-scorpion

AptDzy-DNS shows high efﬁciency for targeted gene therapy

MB-231 cells

nanostructure (termed
AptDzy-DNS)

with good biocompatibility and no side effects

most prevalent diseases that threaten many people all
over the world which have been created through microorganisms. One of the most important goals of cancer
research is to target cancer cells speciﬁcally, which
increases the efﬁcacy of treatment and reduces the side
effects of drugs and genes. Since the aptamers appeared,
we have seen signiﬁcant progress over the past two
decades. To date, various types of anticancer drugs
(such as chemotherapy drugs and siRNAs) have been
successfully delivered to cancer cells in vitro. However,
the successful delivery of gene-based drugs to tumor
tissue after systemic injection of aptamer-based compounds has been achieved only in a low number of
studies. In fact, we need more work before achieving
an aptamer-based agent, including clinical trials and
eventually managing daily cancer patients. The
AS1411 aptamer has been applied in several phases of
a clinical trial and it represents a candidate for approval
by the US Food and Drug Administration (FDA).
Along with advancements in this ﬁeld, the inefﬁcient
transfer of antibiotics to infected cells and controlling the
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side effects and the releasing rate, are considered important issues which may be solved by aptamers. Targeted
therapies for both gene therapy and pathogenic diseases
have been developed based on aptamer hybrid nanocomplexes in recent years to overcome these problems.
Nanotechnology will also play an important role in the
delivery of genes and therapeutic agents in the future. The
creation of nanostructure complexes will enhance the efﬁciency of aptamer transfer and delivery. The large surface
area of NPs can play an important role in the binding of
multiple aptamers and targets simultaneously. However,
there are many challenges to delivering NPs-based genes.
Delivery and increased permeability can be effective in
many cases, such as liposome-based drugs that have been
FDA-approved. However, the half-life of the NPs is
important because if too long, certain nanoparticle chemistries may cause toxicity in different organs, requiring more
optimization and research.
Generally, aptamers can form a constructive interaction
between different types of structures and lead to a positive
selection against any given target. The chemical structure,
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pDNA/PEI/sgc-8c aptamer polyplexes than the pDNA/PEI
polyplex, a higher transfection efﬁciency without signiﬁcantly
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geometry and relative reactivity with targeted molecules
makes them a cost-effective and valuable choice for the
diagnosis of many diseases, therapies and array-based
applications. In addition, different attachment mechanisms
of aptamers with antibiotic molecules provides for precious afﬁnity ligands, making this ﬁeld of research significantly worth it.
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